Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease-Reference-Cited by-同舟云学术

Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

Published:2022-01 Issue:1 Volume:8 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Wang Guoqiao¹²,Liu Lei¹,Li Yan²,Aschenbrenner Andrew J.²,Bateman Randall J.²,Delmar Paul³,Schneider Lon S.⁴,Kennedy Richard E.⁵,Cutter Gary R.⁶,Xiong Chengjie¹²

Affiliation:

1. Division of Biostatistics Washington University School of Medicine St. Louis Missouri USA

2. Department of Neurology Washington University School of Medicine St. Louis Missouri USA

3. F. Hoffmann‐La Roche Ltd. Basel Switzerland

4. Department of Psychiatry and The Behavioral Sciences Department of Neurology Keck School of Medicine University of Southern California Los Angeles USA

5. Department of Medicine University of Alabama at Birmingham Birmingham USA

6. Department of Biostatistics University of Alabama at Birmingham Birmingham USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12286

Reference28 articles.

1. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease

2. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

3. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease